相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
1
20.0%
已完成
1
20.0%
招募中
2
40.0%
终止
1
20.0%
暂无批准数据
- Citizen Health secured $30 million in Series A funding led by 8VC to develop an AI Advocate platform for rare disease patients, bringing total funding to $44 million since December 2023. - The platform has built over 60 communities across 123 rare conditions and achieved a 98.3% patient data-sharing rate, with data already accepted by the FDA for regulatory submissions. - The company plans to launch its AI Advocate to select communities in Q3 2025, focusing on transforming fragmented healthcare into proactive, personalized patient experiences. - With rare diseases affecting over 400 million people globally and 95% lacking approved treatments, the platform addresses critical unmet needs in rare disease care and research.
- A new study reveals that genetic testing in epilepsy patients leads to changes in clinical management in approximately half of the cases. - Clinician-implemented changes based on genetic testing results in improved health outcomes for as many as 75% of patients. - Positive outcomes include a reduction, and in some cases, complete elimination of seizures, highlighting the potential of precision medicine. - The findings support universal genetic testing for all diagnosed epilepsy patients to potentially improve health outcomes and clinical decision-making.
